Man Announces That He Has Synthesized a New Schizophrenia Treatment in His Garage, Based on a Formula Devised by ChatGPT

Key Points:

• Douglas Yao, a biochemist working from a home garage lab, claims to have designed and synthesized a new schizophrenia drug called "PAC-3310" with the help of ChatGPT, modeling it after the antipsychotic Cobenfy but improved.
• Yao states he has designed thousands of small molecule drugs using AI and is testing them in cell lines and mice, aiming to drastically reduce drug development costs compared to traditional pharmaceutical companies.
• Experts highlight the immense challenges Yao faces, noting that drug development typically requires tens of millions to billions of dollars, extensive preclinical and clinical trials, and regulatory approval processes that are difficult for a solo researcher to meet.
• The history of drug development for diseases like Alzheimer’s, where no new drugs have been approved since 2003 despite hundreds of attempts, underscores the complexity and high failure rate in this field, casting doubt on the feasibility of Yao’s approach.
• Online commentators have pointed out the irony and potential risks of relying on ChatGPT—a tool known to sometimes generate misleading information—to create drugs for serious cognitive disorders, with some suggesting Yao’s claims may reflect symptoms of the conditions he aims to treat.